LGC Maine Standards Announces Release of VALIDATE® TUMOR MARKERS and VALIDATE® WHOLE BLOOD GLUCOSE Calibration Verification / Linearity Test Kits

Share Article

VALIDATE® Tumor Markers and VALIDATE® Whole Blood Glucose Address Growing Demand by Laboratories for a Product to Document Calibration Verification / Linearity of Testing System

News Image
Release of VALIDATE® Whole Blood Glucose will allow hospitals to better complete their calibration verification / linearity testing – maximizing reportable ranges while minimizing manual dilutions.

LGC Maine Standards is pleased to announce the release of its VALIDATE® Tumor Markers and VALIDATE® Whole Blood Glucose calibration verification / linearity test kits. VALIDATE® Tumor Markers evaluates Carcinoembryonic Antigen and Cancer Antigens 15-3, 19-9, and 125 in a human serum-based matrix. VALIDATE® Whole Blood Glucose evaluates Glucose in human whole-blood on blood glucose meter systems used in hospital point-of-care settings.

Recently, the US FDA has issued warnings regarding deaths due to interferences with glucose meters used with hospitalized patients and have released a draft guidance that defines new testing and performance requirements for hospital glucose meters and for non-hospital self-monitoring blood glucose devices. Release of VALIDATE® Whole Blood Glucose will allow hospitals to better complete their calibration verification / linearity testing – maximizing reportable ranges while minimizing manual dilutions.

Each VALIDATE® test kit is prepared using the CLSI recommended “equal delta” method for linearity testing and is liquid, ready-to-use. Simply dispense product from dropper bottle and run in replicates.

The addition of VALIDATE® Tumor Markers and VALIDATE® Whole Blood Glucose to the LGC Maine Standards portfolio of products demonstrates a continued commitment to manufacture high-quality calibration verification / linearity products that meet industry needs.

LGC Maine Standards is located in Cumberland Foreside, Maine and manufactures VALIDATE® calibration verification / linearity test kits for over 100 analytes, including General Chemistries, Urine Chemistries, Enzymes, Lipids, HbA1c, Therapeutic Drugs, Cardiac Markers, Thyroids, Serum Proteins, Vitamin D, Tumor Markers, Anemia, Fertility, Whole Blood Glucose, and D-Dimer.

LGC Maine Standards MSDRx® data reduction software is available at no charge for real-time data analysis or, in the United States, a laboratory can send their data to LGC Maine Standards where a technical specialist will complete the data analysis and return a report within five business days.

Contact: LGC Maine Standards
1-800-377-9684
aciccomancini(at)mainestandards(dot)com
http://www.mainestandards.com

###

About LGC
LGC is an international life sciences measurement and testing company with leading positions in growing markets. LGC provides a range of measurement products and services which underpin the safety, health and security of the public, including reference materials and proficiency testing, calibration verification / linearity testing, genomics reagents and instrumentation, and expert sample analysis and interpretation. LGC serves customers across a number of end markets including Pharmaceuticals, Agricultural Biotechnology, Food, Environment, Government and Academia.

LGC’s headquarters are in London and the company employs over 2,000 people, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025, GMP, GLP, ISO Guide 34, ISO/IEC 17043 and ISO 13485:2003.

With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years and is the designated UK National Measurement Institute for chemical and bio measurement. LGC was privatised in 1996 and is now owned by funds affiliated with KKR.

For more information, please visit http://www.lgcgroup.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mary Beltrante
Beltrante PR
+1 (207) 807-0212
Email >
Visit website